Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Ministry Continues Safety Measures On AstraZeneca's Iressa

This article was originally published in PharmAsia News

Executive Summary

Japan's Ministry of Health, Labor and Welfare's Pharmaceutical Safety Committee decided August 1 to continue current safety measures and side effects monitoring regarding AstraZeneca's lung cancer drug Iressa (gefitinib). The committee also summarized and confirmed the drug's clinical benefits. Since last February, the committee has conducted trials comparing gefitinib with other AstraZeneca cancer drugs, and the committee concluded that the results need further analyzing. Iressa has been the center of attention since serious side effects were reported in Japan. (Click here for more - Japanese language

You may also be interested in...



US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.

US Senate Passes First Monograph Reform Bill After House Passed Three

Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.

UsernamePublicRestriction

Register

SC069455

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel